Clinical developments in epigenetic-directed therapies in acute myeloid leukemia.

Blood Advances
Darren PanJohn Mascarenhas

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous disease arising from acquired genetic and epigenetic aberrations which stifle normal development and differentiation of hematopoietic precursors. Despite the complex and varied biological underpinnings, induction therapy for AML has remained fairly uniform over 4 decades and outcomes remain poor for most patients. Recently, enhanced understanding of the leukemic epigenome has resulted in the translational investigation of a number of epigenetic modifying agents currently in various stages of clinical development. These novel therapies are based on mechanistic rationale and offer the potential to improve AML patient outcomes. In light of many recent advances in this field, we provide an updated, clinically oriented review of the evolving landscape of epigenetic modifying agents for the treatment of AML.

References

Aug 2, 2003·Cancer Cell·Ricky W Johnstone, Jonathan D Licht
Apr 27, 2005·Cell·Yuki OkadaYi Zhang
May 6, 2006·Blood·Blanca Sanchez-GonzalezGuillermo Garcia-Manero
May 19, 2006·Cancer Research·Allen S YangJean-Pierre J Issa
Sep 25, 2007·Nature Cell Biology·Ngai CheungChi Wai Eric So
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Jan 20, 2009·Molecular Cell·Mark T Bedford, Steven G Clarke
Jul 11, 2009·Expert Review of Anticancer Therapy·Vince D CataldoAlfonso Quintás-Cardama
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew A Lane, Bruce A Chabner
Nov 12, 2009·Blood·Lars BullingerDirk van den Boom
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Oct 19, 2010·Biochimica Et Biophysica Acta·Radhika A Varier, H T Marc Timmers
Feb 16, 2011·Cell Research·Andrew J Bannister, Tony Kouzarides
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillermo Garcia-ManeroBarry Skikne
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
Aug 5, 2011·Nature·Johannes ZuberChristopher R Vakoc
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Mar 8, 2012·Proceedings of the National Academy of Sciences of the United States of America·Tobias NeffScott A Armstrong

❮ Previous
Next ❯

Citations

Jan 30, 2021·Seminars in Hematology·Sriram SundaravelAmittha Wickrema
Dec 11, 2020·Scientific Reports·Murilo S AmaralSergio Verjovski-Almeida
Mar 11, 2021·Free Radical Biology & Medicine·José-Luis García-GiménezFederico V Pallardó
May 4, 2021·Current Hematologic Malignancy Reports·Hannah McMurryElie Traer
Jun 21, 2020·Developmental Biology·Siba Shanak, Volkhard Helms

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.